Combination of Lonza’s CHOK1SV cell line and BioWa’s Potelligent is expected to give way to technology that produces more potent antibodies.
BioWa and Lonza agreed to bring together their technologies to create a new antibody platform. BioWa’s Potelligent® and Lonza’s GS Gene Expression System™ and CHOK1SV cell line will be combined.
The companies expects to generate a new platform that will produce more potent antibodies with greatly enhanced antibody-dependent cellular cytotoxicity (ADCC) in a high-yield mammalian expression system for industry-wide use.
Under the terms of the agreement, the new Potelligent CHOK1SV cell line will be available for licensing as part of Lonza’s development services in combination with the firm’s GS Gene Expression System. The two companies will jointly market the new technology.
